

1 **Atovaquone for Treatment of COVID-19: A Prospective Randomized, Double-**
2 **Blind, Placebo-Controlled Clinical Trial**

3
4 Mamta K. Jain MD^{1,3*}, James A. de Lemos MD,^{2,3} Darren K. McGuire MD^{2,3}, Colby
5 Ayers PhD², Jennifer L. Eiston B.S.⁴, Claudia L. Sanchez B.S.¹, Dena Kamel B.S.¹,
6 Jessica A. Meisner MD⁵, Emilia V. Thomas MD⁶, Anita A. Hegde MD^{3,6}, Satish Mocherla
7 MD^{1,3}, Joslyn K. Strebe MD³, Xilong Li PhD⁷, Noelle S. Williams PhD⁸, Chao Xing PhD⁹,
8 Mahmoud S. Ahmed PhD², Ping Wang PhD², Hesham A. Sadek MD, PhD^{1,10*}, and John
9 W. Schoggins PhD^{4*}

10

11 ¹ Department of Internal Medicine/Infectious Diseases, University of Texas
12 Southwestern Medical Center, Dallas, Texas 75390, USA

13 ² Department of Internal Medicine/Cardiology, University of Texas Southwestern
14 Medical Center, Dallas, Texas 75390, USA

15 ³ Parkland Health & Hospital System, Dallas, Texas 75235 USA

16 ⁴ Department of Microbiology, University of Texas Southwestern Medical Center,
17 Dallas, Texas 75390, USA

18 ⁵ Department of Internal Medicine/Infectious Diseases, University of Pennsylvania,
19 Philadelphia, Pennsylvania 19104 USA

20 ⁶ Department of Internal Medicine/Hospital Medicine, University of Texas
21 Southwestern Medical Center, Dallas, Texas 75390, USA

22

23 ⁷ Department of Population and Data Science, University of Texas Southwestern
24 Medical Center, Dallas, Texas, 75390, USA

25 ⁸ Department of Biochemistry, University of Texas Southwestern Medical Center,
26 Dallas, Texas 75390, USA.

27 ⁹ McDermott Center for Human Growth and Development, University of Texas
28 Southwestern Medical Center, Dallas, Texas 75390, USA.

29 ¹⁰ Departments Biophysics, and Molecular Biology, and Center for Regenerative
30 Science and Medicine, University of Texas Southwestern Medical Center, Dallas,
31 Texas 75390, USA.

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46 * Author(s) of correspondence

47 **Correspondence to:**

48 **Mamta K. Jain, MD, MPH**

49 Professor of Internal Medicine, Division of Infection Diseases and Geographic Medicine,

50 UT Southwestern Medical Center

51 Mamta.jain@utsouthwestern.edu

52 Tel: (214)648-3111

53

54 **Hesham A. Sadek, MD, PhD**

55 Professor of Internal Medicine/Cardiology, Molecular Biology, and Biophysics, UT

56 Southwestern Medical Center

57 Hesham.sadek@utsouthwestern.edu

58 Tel: (214)648-1413

59

60 **John Schoggins, PhD**

61 Associate Professor of Microbiology, UT Southwestern Medical Center

62 John.schoggins@utsouthwestern.edu

63 Tel: (214)648-3111

64

65 **Word Count: 3067**

66

67

68

69

70 **ABSTRACT**

71

72 **Background:** An in-silico screen was performed to identify FDA approved drugs that
73 inhibit SARS-CoV-2 main protease (M^{pro}), followed by in vitro viral replication assays,
74 and in vivo pharmacokinetic studies in mice. These studies identified atovaquone as a
75 promising candidate for inhibiting viral replication.

76

77 **Methods:** A 2-center, randomized, double-blind, placebo-controlled trial was performed
78 among patients hospitalized with COVID-19 infection. Enrolled patients were
79 randomized 2:1 to atovaquone 1500 mg BID versus matched placebo. Patients
80 received standard of care treatment including remdesivir, dexamethasone, or
81 convalescent plasma as deemed necessary by the treating team. Saliva was collected
82 at baseline and twice per day for up to 10 days for RNA extraction for SARS-CoV-2 viral
83 load measurement by quantitative reverse-transcriptase PCR. The primary outcome
84 was the between group difference in log-transformed viral load (copies/mL) using a
85 generalized linear mixed-effect models of repeated measures from all samples.

86

87 **Results:** Of the 61 patients enrolled; 41 received atovaquone and 19 received placebo.
88 Overall, the population was predominately male (63%) and Hispanic (70%), with a mean
89 age of 51 years, enrolled a mean of 5 days from symptom onset. The \log_{10} viral load
90 was 5.25 copies/mL vs. 4.79 copies/mL at baseline in the atovaquone vs. placebo
91 group. Change in viral load did not differ over time between the atovaquone plus

92 standard of care arm versus the placebo plus standard of care arm. Pharmacokinetic
93 (PK) studies of atovaquone plasma concentration demonstrated a wide variation in
94 atovaquone levels, with an inverse correlation between BMI and atovaquone levels,
95 (Rho -0.45, p=0.02). In post hoc analysis, an inverse correlation was observed between
96 atovaquone levels and viral load (Rho -0.54, p= 0.005).

97
98 **Conclusion:** In this prospective, randomized, placebo-controlled trial, atovaquone did
99 not demonstrate evidence of enhanced SARS-CoV-2 viral clearance compared with
100 placebo. However, based on the observed inverse correlation between atovaquone
101 levels and viral load, additional PK-guided studies may be warranted to examine the
102 antiviral effect of atovaquone in COVID-19 patients.

103
104 *clinicaltrials.gov (NCT04456153).*

105
106
107
108
109
110
111
112
113
114

115

116 INTRODUCTION

117

118 SARS-CoV-2 was identified in late December 2019 as the causative agent of a severe
119 acute respiratory syndrome named COVID-19[1-3]. Targeting the disease in the initial
120 phase with an effective oral agent that can be used in the outpatient setting could
121 mitigate the progression to severe disease and decrease need for hospitalization and
122 mortality. As such, a large number of clinical trials have focused on testing a wide range
123 of antiviral drugs against SARS-CoV-2. A clinicaltrials.gov search at the time this
124 manuscript was written (May 2021), there were over 540 ongoing or completed clinical
125 trials testing potential antiviral agents against SARS-CoV-2. These antivirals include
126 new and repurposed drugs targeting viral proteins that are critical for viral replication
127 such as the proteases (main protease (M^{pro}) and papain-like protease) and RNA
128 polymerase among others. For example, the first FDA approved antiviral drug against
129 SARS-CoV-2 was remdesivir, which was originally developed for the Ebola virus, and
130 has been successfully repurposed as a SARS-CoV-2 RNA polymerase inhibitor.
131 Recently, Merck pharmaceuticals announced that Molnupiravir, an oral anti-viral agent,
132 decreased the risk of hospitalization from COVID-19 by about 30% [4-6]. Also, Pfizer
133 announced the clinical outcomes for their oral SARS-CoV-2 M^{pro} inhibitor, Paxlovid, that
134 reduced risk of hospitalization or death by 89% (within three days of symptom onset)
135 and 88% (within five days of symptom onset) compared to placebo[7, 8]. Both drugs
136 were granted U.S. FDA Emergency Use Authorization. These new drugs however are
137 unlikely to be widely available worldwide soon.

138

139 SARS-CoV-2 is an enveloped, single-stranded RNA betacoronavirus, with a genome
140 size of 29,891 bases encoding for 29 proteins. The SARS-CoV-2 genome encodes
141 several nonstructural proteins including main protease (M^{pro} or $3Cl^{pro}$), and papain-like
142 protease (PL pro)[9]. Given the critical role that these proteins play in viral entry and
143 replication, they have been the topic of intense bench and clinical studies. The first
144 SARS-CoV-2 protein to be crystalized is the M^{pro} protein, which plays a critical role in
145 generation of the viral proteome by cleaving viral polyproteins into individual proteins,
146 resulting in generation of 12 non-structural proteins, including RNA-dependent RNA
147 polymerase and helicase, which are required for viral replication. M^{pro} cleaves its target
148 polypeptides after sequences that include the amino acid glutamine, and its substrate
149 binding pocket is structurally unrelated to any human protease, and thus M^{pro} is a viable
150 drug target for inhibition of SARS-CoV-2 replication [10-12].

151

152

153 A recent study performed an in-silico screen[13], followed by cell-based viral assays
154 with authentic SARS-CoV-2 and identified several FDA approved drugs with antiviral
155 activity. One drug, atovaquone, had an IC50 against SARS-CoV-2 that falls within its
156 therapeutic range, although the antiviral effect of atovaquone does not appear to be
157 primarily mediated by its M^{pro} inhibitory activity[13]. Based on the virocidal,
158 pharmacokinetic and side effect profiles, as well as global drug availability, we chose
159 atovaquone as a candidate for clinical testing. Here we report results of a 2-center,

160 prospective, randomized, placebo-controlled clinical trial examining the antiviral effect of
161 atovaquone in hospitalized COVID-19 patients.

162

163 **METHODS**

164 **Design:** This is a randomized, double-blind, placebo-controlled trial of atovaquone
165 therapy in adult participants hospitalized with COVID-19. Enrollment into the trial began
166 in July 22, 2020 and was completed on December 29, 2020 with 1 month follow-up
167 completed January 26, 2021. There were two clinical trial sites located in Dallas, Texas
168 Eligible participants were randomized in 2:1 fashion to atovaquone or matching placebo.
169 The treatment group received atovaquone 1500mg BID PO for 10 days or matching
170 placebo bid for up to 10 days, during hospitalization and after discharge. Participants
171 could receive all available standard of care therapy under Emergency Use Authorization
172 including remdesivir, dexamethasone and convalescent plasma as prescribed by the
173 treating team. Atovaquone or placebo was administered orally or by nasogastric tube
174 and was given with a meal or snack when possible. The trial protocol was approved by
175 UT Southwestern Institutional Review Board and was overseen by an independent data
176 safety and monitoring board, and all patients provided written informed consent. The
177 trial was funded by a grant from UT Southwestern.

178

179 **Eligibility:** Patients were eligible if they had a positive polymerase chain reaction test for
180 SARS-CoV-2 within 72 hours of hospitalization, ≥ 18 years of age, able to provide
181 informed consent, and anticipated hospitalization for ≥ 48 hours. Patients were excluded
182 if they met any of the following criteria: enrolled in another COVID-19 antiviral therapy,

183 breastfeeding women, known hypersensitivity to atovaquone, treatment with rifampin,
184 patients with AIDS who required treatment for *Pneumocystis jirovecii* or *Toxoplasma*
185 *gondii* , not expected to survive for 72 hours, >14 days from symptom onset.

186

187 Randomized interventions: Atovaquone/placebo: Atovaquone and matching placebo
188 were supplied by Pharmacy Solutions (Arlington, Texas).

189

190 Randomization: Randomization blocks of 12 were given separately to each site
191 pharmacist and after a patient signed informed consent and eligibility was verified, a
192 randomization code was given for each participant.

193

194 Procedures: After randomization, 2 ml of saliva was collected from each participant
195 and mixed with 2 ml of the preservative DNA/RNA Shield (Zymo Research) prior to
196 administration of trial drug, and then repeated every evening and morning while the
197 participant was in the hospital. Saliva, instead of nasopharyngeal swab, was collected
198 because it provides a reliable viral load measurement,[14] and minimizes patient
199 discomfort. Plasma and serum were collected at baseline (Day 1) and Day 3 and 5 of
200 follow-up if still hospitalized. A telephone follow-up occurred at 2 and 4 weeks after
201 randomization if the patient was discharged. All investigators remained blinded to study
202 assignment until completion of follow-up and database lock. The lead investigators were
203 involved in the design, analysis, and writing of the manuscript. Other investigators
204 contributed in collection of data. All investigators reviewed the manuscript. The trial is
205 registered on clincialtrials.gov (NCT04456153).

206

207 **RNA Isolation:** Saliva was collected using the DNA/RNA Shield Saliva Collection Kit
208 (Zymo Research) following the manufacturer's protocol. 1-2 ml of saliva/Shield mix was
209 incubated with DTT (Life Technologies) following the U.S. Department of Health and
210 Human protocol ([https://www.cdc.gov/coronavirus/2019-ncov/downloads/processing-](https://www.cdc.gov/coronavirus/2019-ncov/downloads/processing-sputum-specimens.pdf)
211 [sputum-specimens.pdf](https://www.cdc.gov/coronavirus/2019-ncov/downloads/processing-sputum-specimens.pdf)). The samples were then treated with Proteinase K (Zymo
212 Research) following the manufacturer's protocol. RNA was extracted using the Direct-
213 zol RNA Miniprep Kit (Zymo Research).

214

215 **SARS-CoV-2 positive control:** SARS-CoV-2 N gene was amplified from a synthesized
216 N gene fragment (IDT) with primers that introduced a T7 promoter sequence on the 3'
217 end (IDT). The PCR product was purified using Qiagen PCR Purification Kit (Qiagen). In
218 vitro transcription was performed using T7 RiboMAX Express Large Scale RNA
219 Production System following the manufacturer's protocol (Promega). RNA was
220 quantitated by spectrophotometry on a DS-11 FX instrument (Denovix) and by
221 fluorometer assay using the DeNovix RNA Assay. In vitro transcribed RNA was used to
222 generate a standard curve for qPCR from a 10-fold dilution series starting at 5×10^{10}
223 copies of RNA.

224

225 **RT-qPCR:** RT-qPCR was performed in a 20 μ l reaction containing 5 or 10 μ l RNA, 5 μ l
226 TaqMan Fast Virus 1-Step Master Mix, 600 nM each primer, and 150 nM probe. 10 μ l
227 RNA was used for the detection of SARS-CoV-2 and 5 μ l RNA for detection of GAPDH.
228 SARS-CoV-2 primers and probe were designed as recommended by the Center for

229 Disease Control (<https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer->
230 [probes.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html)). GAPDH primers and probe were designed as previously reported[10]. All
231 oligonucleotides were synthesized by LGC Biosearch Technologies. RT was performed
232 at 50°C for 5 minutes, followed by inactivation at 95°C for 2 minutes, and 40 cycles of
233 PCR (95°C for 3 seconds, 60°C for 30 seconds) on an ABI 7500 Fast thermocycler or a
234 QuantStudio 3 (Applied Biosystems).

235
236 **Analysis of RT-qPCR data.** For each 96-well plate, a standard curve of N gene
237 dilutions was run as described above. A simple linear regression model was used to fit
238 the Ct values from the standard curve and subsequently interpolate RNA concentrations
239 from saliva samples. Across all 96-well plates, the R² value for goodness of fit was 0.97
240 or higher. The lower limit of detection of the assay was 50ng N gene control RNA.
241 GAPDH Ct values were obtained for all samples. Samples that had undetectable
242 GAPDH levels, a total of 7, were removed from the analysis. The GAPDH Ct values of
243 the remaining samples were analyzed using the ROUT method for outlier analysis with
244 a 1% threshold. This resulted in additional 4 samples being removed from the data set.
245 The final data set contained 614 samples. SARS-CoV-2 RNA copies/mL were
246 interpolated from the standard curves, and log-transformed data were analyzed.

247
248 **Outcomes and Statistical Analysis:** Any sample with no detectable GAPDH
249 housekeeping and any with GAPDH Ct >34 was prospectively omitted. Values below
250 detection limit were assigned a value ½ between lowest detection limit and zero. All
251 analyses were intention-to-treat.

252

253 The primary outcome was log transformed viral load (copies/mL) using generalized
254 linear mixed-effect models of repeated measures (GLMM) using data from all samples
255 and timepoints. Random intercepts with an unstructured covariance structure was used
256 in the models. Time point differences were statistically assessed through contrast tests
257 with the appropriate combination of the fixed effects of treatment group, time, and
258 treatment group by time interactions. No adjustment was made for multiple
259 comparisons. Statistical significance was set using $\alpha=0.05$, and all analyses were
260 performed using SAS version 9.4.

261

262 Secondary outcomes were (1) viral load (log copies/mL) at 2 days, 4 days, and 7 days
263 after randomization. (2) Area under the curve (AUC) of viral load (log copies/mL)
264 through day 3 and 7 using the trapezoidal rule. (3) Between group differences in viral
265 load (log copies/mL) using GLMM stratified by morning and evening samples, use of
266 remdesivir, median split of baseline values (high vs. low viral load), median split time
267 from onset of symptoms (<5 days vs. ≥ 5 days, median split of body mass index (BMI),
268 diabetes status, sex and age. (4) Time to 2 log unit decrease in viral load using
269 Kaplan-Meier estimates.

270 Subgroup analyses evaluated the primary endpoint stratified by morning and evening
271 samples, use of remdesivir, sex, diabetes status and median baseline viral load (high
272 vs. low viral load), time from onset of symptoms (<5 days vs. ≥ 5 days), body mass index
273 (BMI), and age. Our exploratory clinical outcome was to examine ≥ 2 point change in

274 ordinal scale (where higher scores are associated with clinical improvement) at Day 5
275 by chi-square analysis as described previously[15].

276

277 **Pharmacokinetic Analysis:** Blood was drawn from participants prior to drug being
278 given on Day 1 (which is baseline). Patients received drug at approximately 5 pm on
279 day 1 then twice per day thereafter (approximately 9 am and 5 pm). Blood was drawn
280 on Day 3 in the morning and Day 5 in the morning (if patient was still in hospital)
281 between 5 and 8 am.

282

283 Analysis of patient specimens utilized standard blood-borne pathogen precautions. Day
284 1 pre-dose samples were pooled and evaluated as blanks. Analysis was blinded to
285 patient group, so samples from patients receiving placebo were analyzed in the same
286 fashion as samples from patients receiving drug. Day 3 and 5 samples were diluted
287 1:25 or 1:50 in a total volume of 50 μ L of commercial human plasma (BioIVT
288 HMPLEDTA2, Lot BRH465874). To all samples, 10 μ L of internal standard
289 (atovaquone-d4) diluted in 30 mM NH₄ Acetate was added and samples vortexed. 400
290 μ L of ethyl acetate was added to each sample. Tubes were vortexed for 30 sec,
291 incubated at room temperature (RT) for 5 minutes and spun for 5 minutes at 16,100 x g.
292 Supernatant was transferred to a second tube. To the first tube, 400 μ L of ethyl acetate
293 was added. Tubes were vortexed for 15 sec, incubated at RT for 5 minutes and spun
294 for 5 minutes at 16,100 x g. Supernatant was removed and added to tube containing
295 supernatant previously collected. Samples were dried down under vacuum and then
296 resuspended in 100 μ L of 20:80 dH₂O:ACN, 5mM NH₄ Acetate. Samples were

297 vortexed for 15 seconds, sonicated for 3 minutes and spun for 5 minutes at 16,100 x g.
298 Supernatant was transferred to an HPLC vial and analyzed on a Sciex 4000QTRAP
299 coupled to a Shimadzu Prominence LC using a fit-for-purpose method. Atovaquone
300 was detected in negative multiple reaction monitoring (MRM) mode using the following
301 transitions: 365.096 to 337.0 (quantitation ion), 365.096 to 170.8 (qualifier ion).
302 Atovaquone-d4 was detected using the 369.1 to 341.0 transition. An isocratic flow of 0.2
303 mL/min 2 mM NH₄ acetate with 0.8 mL/min of acetonitrile on an Agilent C18 XDB
304 column (5-micron, 50 x 4.6 mm) was used for chromatography. Atovaquone and
305 Atovaquone-d4 showed a retention time of 1.73 min using this method. Concentrations
306 were determined by comparison to a 9-point standard curve prepared by spiking blank
307 human plasma with atovaquone standards made in DMSO. Standards and quality
308 control (QC) samples were run twice with 14/18 standards and 7/8 QC's showing back-
309 calculated values with 15% of nominal. The limit of detection (LOD) was defined to be
310 three-fold above the signal observed in blank plasma and the limit of quantitation (LOQ)
311 was defined as the lowest point on the standard curve above the limit of detection and
312 within 20% of nominal. The LOQ was 5 ng/mL. Recovery of analyte at low, medium and
313 high concentrations was >93%. Final atovaquone levels were calculated as µg/ml at
314 days 3 and day 5 following initiation of atovaquone therapy.

315

316 **RESULTS**

317 Of the 61 patients who signed consents, 60 underwent 2:1 randomization; 41 were
318 assigned to atovaquone group and 19 to the placebo group. Overall the population was
319 predominately male and Hispanic with a mean age of 51 years. The two groups were

320 balanced (Table 1) with regard to age, sex, race, co-morbidities, days from onset of
321 symptoms, baseline oxygen requirements, and receipt of COVID-19 specific standard of
322 care treatment. A higher proportion of participants with diabetes were in the atovaquone
323 arm.

324

325 Primary Outcome

326 The log₁₀ viral load was 5.25 copies/mL vs. 4.79 copies/mL at baseline in the
327 atovaquone vs. placebo group and decreased in both groups over time. No differences
328 in viral load over time were seen between the atovaquone plus standard of care arm
329 versus the standard of care arm (**Figure 1A and 1B**).

330

331 Secondary Outcomes

332 Two days after intervention, the viral load was 5.37 copies/mL vs. 4.43 copies/mL in the
333 atovaquone vs. placebo arm. Four days after intervention, the viral load was 4.22
334 copies/mL vs. 3.76 copies/mL and 7 days after the intervention, the viral load was 3.92
335 copies/mL vs. 3.71 copies/mL in atovaquone vs. placebo group. No differences were
336 seen between the groups in any of the days. The AUC for viral load was 36.09 vs.
337 38.39, p=0.76 in the atovaquone compared with the placebo arm. There were no
338 differences between groups in viral load over time in subgroup analyses stratified by
339 sex, age, diabetes, time of sample collection, use of remdesivir, symptom onset of ≥5
340 days vs. <5 days, high versus low viral load. At Day 5, >2 point change in ordinal score
341 occurred in 8 of 41 in atovaquone and 1 of 19 in placebo, p=0.30. At Day 15, >2 point

342 change in ordinal scale occurred in 25 of 40 in atovaquone and 9 of 17 in placebo,
343 $p=0.68$.

344

345 Atovaquone levels

346 Day 3 drug levels (7.668 $\mu\text{g/mL}$) were significantly lower than those on day 5 (11.590
347 $\mu\text{g/mL}$) ($p < 0.01$) (**Figure 2**), suggesting that steady state plasma concentration was
348 not reached by 3 days. Analysis of the correlation between BMI and drug levels
349 revealed a statistically significant inverse correlation between BMI and atovaquone
350 levels, (Spearman rho -0.45, $p = 0.02$) (**Figure 3**). Interestingly, there was an inverse
351 correlation between atovaquone levels and viral load (rho -0.54, $p = 0.005$) (**Figure 4**).

352

353 Safety

354 There were 45 grade 3 or higher adverse events; 30 in the atovaquone arm and 15 in
355 the placebo arm. There were two grade 3 adverse events thought to be related to
356 study drug one in the atovaquone arm and one in the placebo arm. Non-serious
357 adverse events thought to possibly related to study drug included hyponatremia,
358 transaminitis, nausea/vomiting, and diarrhea. Overall, there was a total of 8 (13.3%)
359 deaths in the trial, with 6 (14.6%) vs. 2 (10.5%), $p=0.44$ in the atovaquone vs. placebo
360 group 28 days after intervention.

361

362

363 **DISCUSSION**

364

365 In this prospective, randomized, placebo-controlled clinical trial of 60 patients, no effect
366 on viral clearance was observed in patients treated with atovaquone compared with
367 placebo. This trial was not powered to examine clinical efficacy. The results of present
368 trial also demonstrated that atovaquone in patients hospitalized with COVID-19 was well
369 tolerated. There was no significant difference in either severe adverse events or death
370 in the atovaquone treated group.

371

372 The secondary outcomes and post-hoc analyses highlight several factors that may help
373 explain why atovaquone did not show a significant effect on viral load compared with
374 placebo as pre-specified in the primary outcome. First, the preclinical study that
375 identified atovaquone did not test its antiviral effect *in vivo* in an animal model, and thus
376 the *in vitro* antiviral effect in cell culture might not be directly translatable clinically.
377 Second, atovaquone was administered in a hospitalized patient population, in which
378 almost two-thirds received remdesivir as part of standard of care therapy, and thus it is
379 possible that an antiviral effect of atovaquone was overshadowed by remdesivir.
380 Importantly, although one-third of participants did not receive remdesivir, this study size
381 was too small to allow exploration of the antiviral effects of atovaquone in patients not
382 receiving remdesivir. It is also possible that measuring viral load in upper respiratory
383 samples may not be a sensitive indicator for viral replication.

384

385 Another possibility for not detecting significant changes in viral kinetics in the overall
386 population may be the inability to achieve inhibitory free drug concentration levels in
387 some patients. Atovaquone has a long half-life and is highly plasma protein bound. The

388 present study assessed the highest approved dose of 1500 mg twice daily. Based on
389 PK/PD data from studies of *Pneumocystis jirovecii*[16, 17], and PK studies in
390 rodents[13], it was postulated that IC50-equivalent therapeutic plasma levels could be
391 achieved. Our in vitro data indicated that the free atovaquone IC50 for SARS-CoV-2
392 antiviral activity in Vero cells is 1.2 nM based on a total IC50 of 1.5 μ M and unbound
393 fraction (f_u) for atovaquone of 0.0008 in tissue culture media (N. Williams, unpublished).
394 According to DrugBank, atovaquone is reported to be highly protein bound in plasma
395 (>99.9%). Our preliminary analysis of atovaquone binding to human plasma supports
396 this observation ($f_u = 0.00003$), suggesting that total drug levels of at least 40 μ M (15
397 μ g/mL) are needed. This, of course, assumes that the IC50 calculated in Vero cells is
398 relevant for COVID-19 disease in vivo.

399
400 However, the PK data using samples collected from patients in the present trial indicate
401 that IC50-equivalent drug levels were not achieved in most patients at 3 days after
402 initiation of atovaquone, and only a subset of patients achieved adequate levels at day
403 5. Given that the trial was restricted to patients hospitalized with COVID-19, an antiviral
404 effect during the early phase of the disease, when antivirals are most likely to have a
405 therapeutic effect, was not tested in the current trial.

406
407 Importantly, the results highlight the potential role BMI may play with regard to
408 atovaquone plasma concentrations. The present PK studies revealed two important
409 findings: first, the inverse correlation between atovaquone plasma concentration and
410 BMI is a strong indicator that patients with higher BMI may need higher dosing. Second,

411 an inverse correlation was observed between atovaquone levels and viral load, which
412 could suggest an antiviral effect of atovaquone on SARS-CoV-2 if adequate drug levels
413 are achieved. However, the post-hoc nature of these findings preclude making reliable
414 conclusions, and thus further PK-guided studies may be needed to determine the role of
415 atovaquone in treatment of COVID-19 patients.

416

417

418 **Acknowledgements**

419 This trial was supported by funds from the Mary Kay Family Foundation and the Office
420 of the President, UT Southwestern Medical Center. We are grateful for the following
421 members of the Data Safety and Monitoring Board who reviewed the interim analysis:
422 William M. Lee, MD; Kelly Chin, MD; Justin Grodin, MD; Joan Reish, PhD. We are
423 grateful for Ezimamaka Ajufo, MD and Lorrie Burkhalter for developing data dictionary
424 and RedCap instrument. The clinical team and pharmacy teams who assisted include:
425 Tianna Petersen,MS; Laura Hansen,MS; Minerva Santos, Azadeh Mozaffari, Pharm D;
426 Christine Cha, PharmD; Natalie Dellavalle; PharmD; Sonia Gonzales, PharmD.
427 Pharmacokinetic analyses were conducted by the Preclinical Pharmacology Core at UT
428 Southwestern Medical Center. HAS was funded by Center for Regenerative Science
429 and Medicine at UT Southwestern Medical Center.

430

431

432 **Conflict of interest**

433 MKJ has received research funding from Gilead Sciences and Regeneron and was on
434 Advisory Board for Gilead Sciences. SM received research funding from Regeneron.
435 JAdL has received consulting income from Regeneron and Eli Lilly unrelated to COVID-
436 19. JWS serves as a consultant for the Federal Trade Commission on matters related to
437 COVID-19 treatments.

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456 TABLE 1: Demographics and Clinical Characteristics at Baseline

	Overall N(%)	Atovaquone (n=41) N (%)	Placebo (n=19) N(%)	P value
Gender				
Male	38 (63)	26 (63)	12 (63)	1.0
Race				
White	46 (77)	31 (76)	15 (79)	1.0
Black	8 (13)	6 (15)	2 (11)	
Ethnicity				
Hispanic	42 (70)	29 (71)	13 (68)	1.0
Age, mean yeas (IQR)	50.9 (41.9, 59.6)	51.64 (42.5, 60.8)	49.4 (41, 59.6)	0.56
BMI, mean	32.78 (27,36.5)	32.65(27.1, 35.9)	33.07 (26.8, 37.1)	0.86
Co-morbidities				
Hypertension	38 (63)	26 (63)	12 (63)	1.0
Diabetes	38 (63)	30 (73)	8 (42)	0.04
Obesity	23 (38)	15 (37)	8 (42)	0.78
Chronic kidney disease	20 (33)	12 (29)	8 (42)	0.38
Lung disease [#]	12 (20)	10 (24)	2(11)	0.31
Heart disease [^]	7(12)	5 (12)	2 (11)	1.0
Cancer	6 (10)	3 (7)	3 (16)	0.37

transplant	5 (8)	2 (5)	3 (16)	0.31
liver disease	5 (8)	4 (10)	1 (5)	1.0
Vascular	4 (7)	2 (5)	2 (11)	0.23
Other [*]	3 (5)	1 (2)	2 (11)	0.26
Other treatment				
On remdesivir		27 (66)	9 (47)	0.26
On dexamethasone		30 (73)	14 (74)	1
Plasma		4 (10)	1 (5)	1
Other characteristics				
Days from symptom onset, mean days (IQR)	5.15 (4,6)	5.24 (4,7)	4.95 (4,6)	0.56
Oxygen status at baseline				0.57
Room air	17 (28.3)	10 (24.4)	7 (36.8)	
Low flow oxygen	40 (66.7)	29 (70.7)	11 (57.9)	
High flow oxygen	3 (5)	2 (4.9)	1 (5.3)	

457

458 # Chronic obstructive pulmonary disease, asthma, smoking

459 ^ Congestive heart failure, myocardial infarction, coronary artery disease,
460 cardiomyopathy

461 * Autoimmune, connective tissue, peptic ulcer, HIV

462 **Figure Legends:**

463 **Figure 1. Primary Outcome. A)** Mean log SARS-CoV-2 viral RNA in placebo
464 compared to atovaquone over the 10-day trial period. **B)** Viral load decline in placebo
465 and atovaquone groups. No statistically significant difference was detected between the
466 two groups.

467
468 **Figure 2. Atovaquone Plasma Concentration.** Atovaquone plasma concentration
469 measured at day 3 and 5 following initiation of therapy. Day 3 drug levels were
470 significantly lower than those of day 5. (** $p < 0.005$).

471
472 **Figure 3. Correlation Between Atovaquone Plasma Concentration and BMI.**
473 Pharmacokinetic studies showed a negative correlation between atovaquone and BMI 5
474 days following initiation of atovaquone ($\rho = -0.45$, $p = 0.02$).

475
476 **Figure 4. Correlation Between Atovaquone Plasma Concentration and Viral Load.**
477 Mean log SARS-CoV-2 viral RNA showed an inverse correlation with atovaquone
478 plasma concentration ($\rho = -0.54$, $p = 0.005$).

479

480



481

482

483

484

485 **Figure 1: Primary Outcome**



504

505

506

507

508 **Figure 2. Atovaquone Plasma Concentrations**

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525


526

527

528

529

530



531 **Figure 3. Correlation Between Atovaquone Plasma Concentration and BMI.**

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548


549

550

551

552

553



554 **Figure 4. Correlation Between Atovaquone Plasma Concentration and Viral Load.**

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571


572

573

574

575

576



577 **REFERENCES**

578

579

- 580 1. Malik YS, Sircar S, Bhat S, et al. Emerging novel coronavirus (2019-nCoV)-current scenario,
581 evolutionary perspective based on genome analysis and recent developments. *Vet Q* **2020**;
582 40:68-76.
- 583 2. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in
584 China. *Nature* **2020**; 579:265-9.
- 585 3. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of
586 probable bat origin. *Nature* **2020**; 579:270-3.
- 587 4. Rosenke K, Hansen F, Schwarz B, et al. Orally delivered MK-4482 inhibits SARS-CoV-2
588 replication in the Syrian hamster model. *Nature Communications* **2021**; 12:2295.
- 589 5. Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK-
590 4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. *Nature Microbiology* **2021**; 6:11-8.
- 591 6. Fischer W, Eron JJ, Holman W, et al. Molnupiravir, an Oral Antiviral Treatment for COVID-19.
592 medRxiv : the preprint server for health sciences **2021**:2021.06.17.21258639.
- 593 7. Owen Dafydd R, Allerton Charlotte MN, Anderson Annaliesa S, et al. An oral SARS-CoV-2
594 Mpro inhibitor clinical candidate for the treatment of COVID-19. *Science* **2021**; 374:1586-93.
- 595 8. Mahase E. Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness,
596 company reports. *Bmj* **2021**; 375:n2713.
- 597 9. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2
598 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **2020**.
- 599 10. Mengist HM, Dilnessa T, Jin T. Structural Basis of Potential Inhibitors Targeting SARS-CoV-2
600 Main Protease. *Front Chem* **2021**; 9:622898.
- 601 11. Mohammad T, Shamsi A, Anwar S, et al. Identification of high-affinity inhibitors of SARS-
602 CoV-2 main protease: Towards the development of effective COVID-19 therapy. *Virus Res* **2020**;
603 288:198102.
- 604 12. Yoshino R, Yasuo N, Sekijima M. Identification of key interactions between SARS-CoV-2 main
605 protease and inhibitor drug candidates. *Sci Rep* **2020**; 10:12493.
- 606 13. Mahmoud Ahmed AF, Ping Wang ,Jan N. Boys ,Jennifer L. Eitson ,Maikke B. Ohlson
607 ,Wenchun Fan ,Matthew B. McDougal ,John W. Schoggins ,Hesham Sadek. Identification of
608 Atovaquone as and Mebendazole as Repurposed Drugs with Antiviral Activity against SARS-CoV-
609 2 chemRxiv **2021**; [https://chemrxiv.org/engage/chemrxiv/article-
610 details/612ff2f8abeb6328b6c624cd](https://chemrxiv.org/engage/chemrxiv/article-details/612ff2f8abeb6328b6c624cd).
- 611 14. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva or Nasopharyngeal Swab
612 Specimens for Detection of SARS-CoV-2. *N Engl J Med* **2020**; 383:1283-6.
- 613 15. Davey RT, Jr., Fernandez-Cruz E, Markowitz N, et al. Anti-influenza hyperimmune
614 intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-
615 blind, randomised, placebo-controlled trial. *Lancet Respir Med* **2019**; 7:951-63.

- 616 16. Robin C, Le MP, Melica G, et al. Plasma concentrations of atovaquone given to
617 immunocompromised patients to prevent *Pneumocystis jirovecii*. *J Antimicrob Chemother*
618 **2017**; 72:2602-6.
- 619 17. Calderon MM, Penzak SR, Pau AK, et al. Efavirenz but Not Atazanavir/Ritonavir Significantly
620 Reduces Atovaquone Concentrations in HIV-Infected Subjects. *Clin Infect Dis* **2016**; 62:1036-42.
621